- Conditions
- Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, NSCLC, KRAS G12C, Metastatic Lung Cancer, Advanced Lung Carcinoma
- Interventions
- BBO-8520, Pembrolizumab, BBO-10203
- Drug
- Lead sponsor
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • La Jolla, California • San Francisco, California + 18 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 1,466
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Patients With Non-Small Cell Lung Cancer
- Interventions
- OSE2101, Docetaxel, NGS HLAA2 assay
- Drug · Device
- Lead sponsor
- OSE Immunotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 363 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 79
- States / cities
- Beverly Hills, California • Encino, California • Los Angeles, California + 56 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Cabozantinib, Atezolizumab, Docetaxel
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 366 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 12
- States / cities
- Palo Alto, California • San Diego, California • Santa Barbara, California + 9 more
- Conditions
- Melanoma, Carcinoma, Non-Small- Cell Lung
- Interventions
- SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed, carboplatin
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 23
- States / cities
- Springdale, Arkansas • Los Angeles, California • San Francisco, California + 18 more
- Conditions
- Adenocarcinoma of the Lung, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Interventions
- crizotinib, pemetrexed disodium, laboratory biomarker analysis, pharmacological study
- Drug · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 167
- States / cities
- Sacramento, California • Aurora, Colorado • Colorado Springs, Colorado + 111 more
- Conditions
- Non Small Cell Lung Cancer, Metastasis, Recurrence
- Interventions
- Pembrolizumab, Idelalisib
- Drug
- Lead sponsor
- Asha Nayak
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Lung Cancer
- Interventions
- pemetrexed disodium, sorafenib tosylate
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 207
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 124 more
- Conditions
- Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Ovarian Cancer
- Interventions
- PF-07257876
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 25 more
- Conditions
- B-Cell Neoplasm, Estrogen Receptor Negative, HER2/Neu Negative, Metastatic Renal Cell Cancer, Progesterone Receptor Negative, Stage III Mesothelioma, Stage III Renal Cell Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Mesothelioma, Stage IV Non-Small Cell Lung Cancer, Stage IV Renal Cell Cancer, Triple-Negative Breast Carcinoma
- Interventions
- 18F-FSPG, 18F-FDG
- Drug
- Lead sponsor
- Andrei Iagaru
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Carcinoma, Non-Small-Cell Lung, Mesothelioma
- Interventions
- LBH589
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 4
- States / cities
- Fayetteville, Arkansas • Augusta, Georgia • Chicago, Illinois + 1 more
- Conditions
- Lung Cancer, Non-Small Cell
- Interventions
- Niraparib, Pembrolizumab, Placebo
- Drug · Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 666 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 21
- States / cities
- Fullerton, California • Los Angeles, California • Lone Tree, Colorado + 18 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- LGX818
- Drug
- Lead sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Metastatic Non Small Cell Lung Cancer
- Interventions
- LN-145
- Biological
- Lead sponsor
- Iovance Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 46
- States / cities
- Gilbert, Arizona • Duarte, California • La Jolla, California + 37 more
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Osimertinib, Tegavivint, Echocardiography Test, Multigated Acquisition Scan, Computed Tomography, FDG-Positron Emission Tomography, Biospecimen Collection
- Drug · Procedure
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Carcinoma, Non-Small Cell Lung
- Interventions
- CPG 7909, Chemotherapy
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 17
- States / cities
- Gilroy, California • Los Angeles, California • Palm Springs, California + 14 more
- Conditions
- Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Interventions
- PF-07248144, Fulvestrant, Letrozole, Palbociclib, PF-07220060, PF-07850327, ARV-471, vepdegestrant
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 23
- States / cities
- Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 11 more
- Conditions
- Advanced Solid Tumors, Metastatic Solid Tumors
- Interventions
- PF-06939999 dose escalation, PF-06939999 monotherapy, PF-06939999 in combination with docetaxel
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 22
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Pasadena, California + 10 more
- Conditions
- Colon Cancer Metastatic, Head and Neck Cancer Metastatic, Metastatic Non-Small Cell Lung Cancer, Urothelial Carcinoma, Metastatic Melanoma
- Interventions
- ADXS-NEO, Pembrolizumab
- Biological
- Lead sponsor
- Advaxis, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Los Angeles, California • New Orleans, Louisiana + 2 more
- Conditions
- Lung Cancer, Lung Cancer (NSCLC), Locally Advanced NSCLC, Metastatic NSCLC - Non-Small Cell Lung Cancer
- Interventions
- Olomorasib, Pembrolizumab
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- AZD6244, docetaxel, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 1 more
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Interventions
- sorafenib tosylate, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Interventions
- Hsp90 inhibitor AUY922, pemetrexed disodium, pharmacological study, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Interventions
- docetaxel, pemetrexed disodium, gemcitabine hydrochloride, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Non-Small Cell Lung Cancer, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation
- Interventions
- STX-721/PFL-721 (Escalated), STX-721/PFL-721 (3 dose levels), STX-721/PFL-721 (RP2D)
- Drug
- Lead sponsor
- Pierre Fabre Medicament
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 345 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 9
- States / cities
- Duarte, California • Huntington Beach, California • Irvine, California + 6 more